Understanding Breast DCIS diagnosis, coding, and documentation? Learn about Ductal Carcinoma In Situ, also known as non-invasive breast cancer. This resource provides information on clinical terms, healthcare guidelines, and medical coding for Breast DCIS for accurate documentation and patient care. Find details on diagnosis, staging, and treatment options for DCIS.
Also known as
In situ neoplasms of breast
Non-invasive breast cancers confined to the milk ducts.
Malignant neoplasm of breast
Invasive breast cancers that have spread beyond the milk ducts.
Encounter for screening mammogram for malignant neoplasm of breast
Routine mammogram screening for breast cancer detection.
Personal history of malignant neoplasm of breast
Indicates a past diagnosis of invasive breast cancer.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the DCIS purely intraductal?
When to use each related code
| Description |
|---|
| Non-invasive breast cancer cells within milk ducts. |
| Invasive breast cancer spread beyond milk ducts. |
| Abnormal breast cells with increased risk of cancer. |
Missing or incorrect laterality (right, left, bilateral) can impact treatment and staging data accuracy, leading to reimbursement issues.
Incomplete documentation of DCIS subtype (e.g., comedo, cribriform) may affect accurate coding and subsequent treatment planning.
Insufficient documentation differentiating DCIS from invasive ductal carcinoma (IDC) can lead to miscoding and incorrect treatment protocols.
Q: What are the most effective surgical management strategies for low-grade DCIS with microcalcifications detected on mammography in premenopausal women?
A: Surgical management of low-grade ductal carcinoma in situ (DCIS) with microcalcifications in premenopausal women typically involves either breast-conserving surgery (lumpectomy) with radiation therapy or mastectomy. The choice depends on factors like the extent of DCIS, multifocality, patient preference, and family history. For small, low-grade, unifocal lesions, lumpectomy with radiation is often sufficient. However, mastectomy may be considered if achieving negative margins is challenging or if the patient has a strong family history of breast cancer. Sentinel node biopsy is generally not indicated for pure DCIS. Explore how oncotype DX testing can help personalize treatment decisions in certain DCIS cases. Consider implementing a risk-stratified approach to surveillance based on clinicopathologic features and patient preferences.
Q: How can I differentiate DCIS from invasive breast cancer on imaging and biopsy, and what are the key pathological features that distinguish these diagnoses?
A: Differentiating ductal carcinoma in situ (DCIS) from invasive breast cancer requires careful evaluation of both imaging and pathology findings. On mammography, DCIS often presents as microcalcifications, while invasive breast cancer may appear as a mass or architectural distortion. Ultrasound may show a mass or ductal changes for both. Biopsy is crucial for definitive diagnosis. Histologically, DCIS is characterized by the proliferation of malignant cells confined within the breast ducts, without invasion of the basement membrane. Invasive breast cancer, on the other hand, demonstrates stromal invasion by malignant cells. Key pathological features distinguishing DCIS include comedonecrosis, nuclear grade, and architectural pattern (e.g., cribriform, micropapillary, solid). Learn more about the specific immunohistochemical markers that can be used to further refine the diagnosis and prognosticate DCIS. Consider implementing a multidisciplinary approach to diagnosis involving radiologists, pathologists, and surgeons.
Patient presents with concerns regarding breast changes. The patient reports [mention specific symptom, e.g., no palpable lump, but an abnormal mammogram finding]. Mammography reveals [describe mammographic findings, e.g., microcalcifications in the upper outer quadrant of the left breast]. Subsequent biopsy confirms a diagnosis of ductal carcinoma in situ (DCIS), also known as non-invasive breast cancer or stage 0 breast cancer. The DCIS is [specify grade, e.g., high-grade] and [specify nuclear grade, e.g., with comedonecrosis]. Immunohistochemical staining results are [describe ER, PR, and HER2 status]. Surgical options, including lumpectomy with sentinel node biopsy and mastectomy, were discussed with the patient. The risks and benefits of breast conserving surgery versus mastectomy, including the potential need for adjuvant radiation therapy, were thoroughly explained. The patient's decision regarding surgical management will be documented in a subsequent note. Differential diagnoses considered included atypical ductal hyperplasia and invasive ductal carcinoma. ICD-10 code D05.9 is documented for breast DCIS, unspecified. Patient education was provided regarding breast cancer screening, DCIS prognosis, and follow-up care. The patient will schedule a follow-up appointment to discuss the surgical plan and address any further questions.